Quarterly Activities/Appendix 4C Cash Flow Report
Released
Released
Announcement PDF
Tetratherix Limited 2026
Q1 FY27 Quarterly
Activities Report
Tetratherix Limited
ACN 607 771 077
ASX:TTX
01
PRP is a concentrate of the patient’s own growth factors. It is
widely used in orthopaedics and sports medicine, but it tends to
disperse from where it is needed. In a preclinical tendon repair
study, PRP delivered with TegenEOS remained at the repair site
and showed increased benefit compared to PRP alone. This
positions TegenEOS both as a bone graft carrier (as is being
currently routed through the FDA 510(k) process) and as a
delivery vehicle for biologics, which broadens the opportunity
with our planned orthopaedic partners.
TegenEOS shown to be an effective carrier
for platelet-rich plasma (PRP), sharpening
our orthopaedic commercialisation strategy
Tetratherix Limited 2026
Q1 FY27 Quarterly Activities Report
02
All patients across the three cohorts of the TetraDerm surgical
scar trial have now been treated. Patients are in 12-month
follow-up. The trial is blinded, so results cannot be reported until
the data are unblinded, although feedback from clinical
investigators to date has been very encouraging. With
treatment now complete, TTX has officially opened substantive
partnering discussions for TetraDerm’s global launch.
TetraDerm clinical trial: Full recruitment and
treatment completed - results now building.
03
Optimatrix is a gel used during cataract surgery to protect the eye.
To stress-test safety, the full amount of the product was
deliberately left inside the eye in a recognised animal model. Even
so, eye pressure in the treated eyes was lower than in the control
eyes in every animal. Current commercial products available must
be fully removed, which takes time and still may cause eye pressure
spikes and other complications. The FDA has been engaged on the
regulatory pathway and confirmed product code and classification.
Positive first preclinical read-out for
Optimatrix in cataract surgery.
04
05
First STEPP product dispatched for in-
market testing in first cohort of patients
with positive results from initial cohort
06
MDSAP audit completed with no major non-
conformities; new manufacturing campus
on track to open in Q2 FY27.
The FDA’s review has confirmed the core elements of the
submission, including device classification, the nominated
predicate device and the performance testing data. The FDA has
requested further detail on chemical characterisation and final
product labelling, which is largely administrative. The experienced
thoroughness in FDA’s process was expected considering the
novelty of the material, and will establish TTX’s regulatory
leverage for its future product launches. TTX regards this update
as material validation of both the submission and the
Tetramatrix™ platform.
Substantive review update from the US
Food and Drug Administration (FDA) on the
TTX Tegenix 510(k) submission.
ASX Release
ASX:TTX
Anchored by Science
Key highlights for the quarter
Q1 FY27 marks TTX’s entry into commercial operation. The Tetramatrix™ platform is now generating product revenue via its early
supply to commercial partners, its quality systems have been tested against international standards, and its pipeline continues to
widen across surgical specialties. The quarter followed the sequence at the heart of TTX’s platform-to-product strategy: prove
the chemistry, build the manufacturing and quality base, then supply partners who carry each product to market. That sequence
is now running across several products at once. With a strong balance sheet, a manufacturing campus opening this quarter and
partner demand building ahead of full commercialisation in 2027, TTX enters Q2 with momentum and clear line of sight to its FY27
objectives.
2
30 October 2026
In August, TTX shipped its first commercial supply of
Tetramatrix™ polymer, branded STEPP, to our US partner
Superpower Health Inc. This generated the Company’s first
product revenue for the material. The supply supports a
usability & efficacy study of approximately 1,000 people within
our partner’s US network, capturing real-world data ahead of a
full launch in 2027. Initial patient results have been very
encouraging with usability points achieved while avoiding
adverse events commonly seen from injectable GLPs. TTX
and Superpower have now finalised the compounding
formulation for the first nasal spray product in the consumer
metabolic health market. In addition, the underlying STEPP
science was published in the peer-reviewed International
Journal of Pharmaceutics.
BSI completed the Medical Device Single Audit Program
(MDSAP) audit across both TTX sites. It raised no major
non-conformities, all required actions are being closed out.
MDSAP is a single audit that meets the quality system
requirements of five major markets, including Australia and
the US. Certification is expected from BSI in the coming
months. The new Southend campus in Alexandria hosted
the auditors and successfully completed a full product
dispatch demonstration. Once open, the new TTX campus
will increase production capacity approximately 15-fold
ahead of full platform commercialisation in 2027.
Financial commentary:
Strong cash on hand position of $26.4 million as at 30 September 2026, with zero debt financing.
$1.2 million cash inflows in Q1 FY27 driven by Industry Growth Program (IGP) grant and interest income
($8.0) million cash decrease for Q1 FY27. Key driver for the quarter is the capital expenditure for TTX’s new advanced
manufacturing facility (equating to nearly 50% of the total), as well as continued investment in R&D, payment of FY26
employee short term incentives and ongoing listed costs and working capital expenditure. As such, our realised cash outflow
for the operating activities for the quarter is $4.1 million.
Tegenix
Tutelix
TetraDerm
STEPP
TegenEOS
Optimatrix
Operations
FDA
Clearance
First Final Product
Dispatch to Henry
Schein
Jurisdictional
Market Expansion
US Market
Seeding
FDA
Clearance
Supply and Licensing
Agreement Execution
First Final Product
Dispatch to US Partner
Jurisdictional
Market Expansion
First patients in
the Pivotal Trial
IDE Approval from FDA for
the US Arm of the Pivotal
Indication Expansion -
FDA pre-submission
Tutelix
Capital
Raise
Preclinical Data
Read-out
FDA Pre-submission &
Regulatory Pathway
US / AU
Capital Raise
Interim Technical
Reporting with Alcon
First-in-
Human
Cohort 3
Treatment
Completion
Indication
Expansion
FDA Engagement for
Product Designation
Global Partnership
Window Open
First Polymer
Dispatch (STEPP)
STEPP Sale
Revenue
Metabolic
Interim Data
Indication
Expansion
STEPP
Clinical Trial
Metabolic Data
Read out
Team expansion - Digital,
Customer Success and
Production
MDSAP
Stage 2 Audit
New Facility and
HQ site opening
MDSAP
Certification
Embed AI (Artificial
Intelligence) into
ways of working
Will Knox, CEO, said:
Q1 was a defining quarter as TTX moved from development into commercial supply. We shipped our first commercial product,
completed our MDSAP audit with no major findings, and delivered positive preclinical results in ophthalmology and in orthopaedic
biologics delivery (further building our platform pipeline). Since quarter end, the FDA’s substantive review has confirmed the core
elements of our Tegenix 510(k) submission, and we are working with our partners on a prompt response to ensure timely launch of
Tegenix in the US market. With our new manufacturing campus opening this quarter, we are well placed to meet growing partner
demand.
ASX Release
ASX:TTX
FY27 Strategic Priorities
3
Tetratherix Limited 2026 Anchored by Science
Key highlights for the quarter
TTX’s Investor Hub platform provides existing and prospective shareholders real‑time access to ASX announcements, reports
and presentations. You can visit at:
Authorised for release by the Board.
For further information contact:
Jacob Pfeffer
General Counsel | Company Secretary
+61 425 194 200
jacob.pfeffer@tetratherix.com
Forward looking statements: this announcement may contain forward-looking statements which may be identified by words
such as “believes”, “considers”, “could”, “estimates”, “expects”, “intends”, “may”, and other similar words that involves risks and
uncertainties. Such statements are not guarantees of future performance and involve known and unknown risks, uncertainties,
assumptions and other important factors, many of which are beyond the control of TTX or its Directors and management and
could cause TTX’s actual results and circumstances to differ materially from the results and circumstances expressed or
anticipated in these statements. The Directors cannot and do not give any assurances that the results, performance, or
achievements expressed or implied by the forward-looking statements contained in this announcement will actually occur and
investors are cautioned not to place undue reliance on these forward-looking statement.
ASX Release
ASX:TTX
4
Tetratherix Limited 2026 Anchored by Science
FY27 Q1 4C
Appendix
5
Tetratherix Limited 2026 Anchored by Science
REF Comment
1 - 4
R&D costs include specific projects, directly attributable staff, research and laboratory costs, trademarks, patent filing, and
upkeep. Specific breakdown by project as follows.
1
Bone Regeneration: activity focused on preparation for FDA clearance for Tegenix and TegenEOS, with spending front weighted
in FY26. Industry Growth Program (IGP) grant funding incremental to the UOF has been allocated to this franchise resulting in
spend in excess of prospectus assumptions.
2 Tissue Healing: ongoing clinical trial and pipeline development for TetraDerm.
3 Tissue Spacing: relates to Optimatrix clinical trial spend. Tutelix™ is funded by the joint venture.
4
Precision Medicine: relates to nasal drug delivery R&D. Superpower licence income is supporting incremental spend versus the
Prospectus UOF.
5
Manufacturing expansion: a new lease was signed in August 2025. Capital expenditure investment continues to commission our
advanced manufacturing facility. Industry Growth Program (IGP) funding and May 2026 placement incremental to the UOF, will
support funding to expedite the addition of Manufacturing Pods & automation.
6
Listed company costs: Reflects board remuneration, audit fees, share registry, directors’ and officers’ insurance and company
secretary services.
7 IPO costs: All invoices have now been paid; in line with prospectus assumptions.
8 Working capital: Includes staff (ex R&D), interest, and general operating expenses.
9
Proceeds from the IPO of $33.2m included $8.2m cash as at 30/4/25 and $25.0 million capital raise 30/6/2025.
It excludes $15.6m (before costs) from the May 2026 placement.
$26.3m closing cash balance as at 30 September 2026.
Cash outflows: Q1 FY27 cash balance decrease of ($8.0) million of which ($6.1) relates to spend under the prospectus UOF.
Funds raised at the IPO continue to be deployed as disclosed in the prospectus. Use of Funds May 2025- September 2026
cumulative total ($26.4) million. Cash outflows incremental to the prospectus UOF are funded by incremental cash inflows
highlighted below.
Cash inflows May 2025- September 2026 cumulative total $22.7m including $1.2m in Q1 FY27
$14.7m cash injection from May 2026 placement*
$4.2m Superpower licence fee receipt *
$2.4 m from Industry growth program grant *
$1.4 m from R&D tax incentive
These additional inflows are funding further growth beyond the commitments set out in the IPO strategic plan, accelerating TTX’s
transition from an R&D to a commercially scalable organisation.
* Incremental funding versus prospectus at 94% of inflows ($21.3 million)
USE OF FUNDS
" Prospectus
A$m "
May 25-Sep 26 Actual as % prospectus Ref
Research and Development Bone Regeneration 2.4 2.8 115% 1
Research and Development Tissue Healing 5.3 1.5 28% 2
Research and Development Tissue Spacing 2.3 1.2 53% 3
Research and Development Precision Medicine 1.3 1.4 102% 4
Manufacturing expansion 10.2 10.2 100% 5
Listed company costs and directors fees 2.5 2.1 81% 6
Costs of the offer ($0.4m expensed YTD Apr 25) 3.4 3.4 100% 7
Working capital 5.8 3.8 66% 8
Total Cash outflows 33.2 26.4 79% 9
In accordance with ASX Listing Rule 4.7C TTX provides the following use of funds (UOF) information:
APPENDIX 1
The UOF information relates to the activities outlined in the prospectus relating to 30 June 2025 IPO. Activities outlined in the May 2026
placement, to fund incremental growth over and above the IPO strategic plan are excluded from this analysis.
6
ASX Release
ASX:TTX
Tetratherix Limited 2026 Anchored by Science
Name of entity
ABN Date
72 607 771 077 Sep 30, 2026
Appendix 4C Quarterly cash flow report for entities
subject to Listing Rule 4.7B
Consolidated statement of cash flows Current quarter
"Year to date
(3 months)"
$A’000 $A’000
1 Cash flows from operating activities
1.1 Receipts from customers 7 7
1.2 Payments for: - -
1.2 (a) - research and development (918) (918)
1.2 (b) - product manufacturing and operating costs (210) (210)
1.2 (c) - advertising and marketing (6) (6)
1.2 (d) - leased assets (78) (78)
1.2 (e) - staff costs (2,861) (2,861)
1.2 (f) - administration and corporate costs (795) (795)
1.3 Dividends received (see note 3) - -
1.4 Interest received 346 346
1.5 Interest and other costs of finance paid (136) (136)
1.6 Income taxes paid - -
1.7 Government grants and tax incentives 818 818
1.8 Other (net GST paid) (267) (267)
1.9 Net cash from / (used in) operating activities (4,100) (4,100)
2 Cash flows from investing activities Current quarter
"Year to date
(3 months)"
2.1 Payments to acquire or for:
2.1 (a) - entities - -
2.1 (b) - businesses - -
2.1 (c) - property, plant and equipment (3,650) (3,650)
2.1 (d) - investments - -
2.1 (e) - intellectual property - -
2.1 (f) - other non-current assets - -
7
Tetratherix Limited 2026 Anchored by Science
ASX Release
ASX:TTX
Cash flows from investing activities (Cont.) Current quarter
"Year to date
(3 months)"
$A’000 $A’000
2.2 Proceeds from disposal of: - -
2.2 (a) - entities - -
2.2 (b) - businesses - -
2.2 (c) - property, plant and equipment - -
2.2 (d) - investments - -
2.2 (e) - intellectual property - -
2.2 (f) - other non-current assets - -
2.3 Cash flows from loans to other entities - -
2.4 Dividends received (see note 3) - -
2.5 Other (Contingent consideration payments) - -
2.6 Net cash from / (used in) investing activities (3,650) (3,650)
3 Cash flows from financing activities Current quarter
"Year to date
(3 months)"
3.1
Proceeds from issues of equity securities (excluding convertible
debt securities)
-
3.2 Proceeds from issue of convertible debt securities - -
3.3 Proceeds from exercise of options - -
3.4
Transaction costs related to issues of equity securities or convertible
debt securities
(45) (45)
3.5 Proceeds from borrowings - -
3.6 Repayment of borrowings - -
3.7 Transaction costs related to loans and borrowings - -
3.8 Dividends paid - -
3.9 Other (leased assets) (142) (142)
3.10 Net cash from / (used in) financing activities (187) (187)
4 Net increase / (decrease) in cash and cash equivalents for the period Current quarter
"Year to date
(3 months)"
4.1 Cash and cash equivalents at beginning of period 34,365 34,365
4.2 Net cash from operating activities (item 1.9 above) (4,100) (4,100)
4.3 Net cash used in investing activities (item 2.6 above) (3,650) (3,650)
4.4 Net cash from financing activities (item 3.10 above) (187) (187)
4.5 Effect of movement in exchange rates on cash held (76) (76)
4.6 Cash and cash equivalents at end of period 26,352 26,352
8
Tetratherix Limited 2026 Anchored by Science
ASX Release
ASX:TTX
Appendix 4C Quarterly cash flow report for entities
subject to Listing Rule 4.7B
$A,000 $A,000
5
Reconciliation of cash and cash equivalents at the end of the
quarter (as shown in the consolidated statement of cash flows) to
the related items in the accounts
Current quarter Previous quarter
$A’000 $A’000
5.1 Bank balances 26,302 34,315
5.2 Call deposits 50 50
5.3 Bank overdrafts - -
5.4 Other (provide details) - -
5.5
Cash and cash equivalents at end of quarter (should equal item 4.6
above)
26,352 34,365
6 Payments to related parties of the entity and their associates Current quarter
$A’000
6.1
Aggregate amount of payments to related parties and their associates included in
item 1
919
6.2
Aggregate amount of payments to related parties and their associates included in
item 2
-
6.1 Note
In accordance with ASX Listing Rule 4.7C.3, Tetratherix advises that an amount of
$919k was paid to related parties and associates. These payments comprised:
$870k for executive and non-executive directors’ salaries, superannuation, and
$49k in directors’ salaries paid to entities associated with directors.
-
7
Financing facilities Note: the term “facility" includes all forms of
financing arrangements available to the entity.
Total facility amount
at quarter end
Amount drawn at
quarter end
Add notes as necessary for an understanding of the sources of
finance available to the entity.
$A’000 $A’000
7.1 Loan facilities - -
7.2 Credit standby arrangements - -
7.3 Other (please specify) - -
7.4 Total financing facilities - -
7.5 Unused financing facilities available at quarter end - -
7.6
Include in the box below a description of each facility above,
including the lender, interest rate, maturity date and whether it is
secured or unsecured. If any additional financing facilities have been
entered into or are proposed to be entered into after quarter end,
include a note providing details of those facilities as well.
N/A
9
Tetratherix Limited 2026 Anchored by Science
ASX Release
ASX:TTX
Appendix 4C Quarterly cash flow report for entities
subject to Listing Rule 4.7B
8 Estimated cash available for future operating activities $A’000
8.1 Net cash from / (used in) operating activities (item 1.9) (4,100)
8.2 Cash and cash equivalents at quarter end (item 4.6) 26,352
8.3 Unused finance facilities available at quarter end (item 7.5) -
8.4 Total available funding (item 8.2 + item 8.3) 26,352
8.5 Estimated quarters of funding available (item 8.4 divided by item 8.1) 6.43
Note: if the entity has reported positive net operating cash flows in item 1.9, answer
item 8.5 as “N/A”. Otherwise, a figure for the estimated quarters of funding
available must be included in item 8.5.
8.6
If item 8.5 is less than 2 quarters, please provide answers to the following
questions:
8.6.1
Does the entity expect that it will continue to have the current level of net
operating cash flows for the time being and, if not, why not?
Answer: N/A
8.6.2
Has the entity taken any steps, or does it propose to take any steps, to raise
further cash to fund its operations and, if so, what are those steps and how likely
does it believe that they will be successful?
Answer: N/A
8.6.3
Does the entity expect to be able to continue its operations and to meet its
business objectives and, if so, on what basis?
Answer: N/A
10
Tetratherix Limited 2026 Anchored by Science
ASX Release
ASX:TTX
Appendix 4C Quarterly cash flow report for entities
subject to Listing Rule 4.7B
Q1 FY27 Quarterly Activities Report
This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule
19.11A.
This statement gives a true and fair view of the matters disclosed.
Date: 30 October 2026
Authorised by the Board
(Name of body or officer authorising release – see note 4)
Notes
1.This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the
entity’s activities for the past quarter, how they have been financed and the effect this has had on its cash position. An
entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is
encouraged to do so.
2.If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions
in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly cash flow report has been
prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the
corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing
activities, depending on the accounting policy of the entity.
4.If this report has been authorised for release to the market by your board of directors, you can insert here: “By the
board”. If it has been authorised for release to the market by a committee of your board of directors, you can insert here:
“By the [name of board committee – e.g. Audit and Risk Committee]”. If it has been authorised for release to the market
by a disclosure committee, you can insert here: “By the Disclosure Committee”.
5.If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out
as complying with recommendation 4.2 of the ASX Corporate Governance Council’s Corporate Governance Principles
and Recommendations, the board should have received a declaration from its CEO that, in their opinion, the financial
records of the entity have been properly maintained, that this report complies with the appropriate accounting
standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the
basis of a sound system of risk management and internal control which is operating effectively.
COMPLIANCE STATEMENT
11
Tetratherix Limited 2026 Anchored by Science
ASX Release
ASX:TTX
Share your feedback
Discover